Discussion stirs around Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) this week; here is what analysts are saying.

April 23, 2018 - By Richard Conner

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) LogoInvestors sentiment decreased to 1.19 in Q4 2017. Its down 1.02, from 2.21 in 2017Q3. It turned negative, as 11 investors sold Tetraphase Pharmaceuticals, Inc. shares while 25 reduced holdings. 16 funds opened positions while 27 raised stakes. 29.51 million shares or 0.43% more from 29.38 million shares in 2017Q3 were reported.
Bankshares Of Mellon Corp has 234,864 shares for 0% of their portfolio. Fmr Llc holds 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) or 989,234 shares. Bridgeway Capital Mgmt Incorporated holds 0.01% or 79,800 shares. Credit Suisse Ag holds 26,094 shares. Royal Natl Bank Of Canada owns 200 shares. New York-based Citigroup has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Moreover, Jacobs Levy Equity Mngmt has 0.02% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Deutsche National Bank Ag reported 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). New York State Common Retirement Fund holds 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) or 44,300 shares. Axa has 0.01% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). International Inc reported 0% of its portfolio in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Geode Management Limited Liability Corporation has 0% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 427,767 shares. Quantbot Technologies L P invested in 0% or 6,528 shares. Ameritas Invest invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Hudson Bay Capital Mgmt Lp reported 500,000 shares.

Since January 9, 2018, it had 0 insider buys, and 2 insider sales for $98,932 activity.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Among 6 analysts covering Tetraphase Pharmaceutical (NASDAQ:TTPH), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Tetraphase Pharmaceutical had 10 analyst reports since February 12, 2018 according to SRatingsIntel. FBR Capital maintained the shares of TTPH in report on Wednesday, March 7 with “Buy” rating. The firm earned “Buy” rating on Tuesday, February 27 by FBR Capital. The firm has “Buy” rating by FBR Capital given on Wednesday, February 21. The firm earned “Buy” rating on Thursday, March 29 by Gabelli. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Buy” rating given on Monday, February 12 by FBR Capital. BMO Capital Markets maintained Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) rating on Thursday, March 8. BMO Capital Markets has “Market Perform” rating and $3 target. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Buy” rating given on Wednesday, February 14 by SunTrust. As per Wednesday, February 14, the company rating was downgraded by BMO Capital Markets. Below is a list of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) latest ratings and price target changes.

29/03/2018 Broker: Gabelli Old Rating: Hold New Rating: Buy Upgrade
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $2.75 New Target: $3 Maintain
07/03/2018 Broker: FBR Capital Rating: Buy Maintain
27/02/2018 Broker: FBR Capital Rating: Buy New Target: $6.0 Maintain
23/02/2018 Broker: WBB Securities Rating: Speculative Buy New Target: $6 Initiates Coverage On
21/02/2018 Broker: FBR Capital Rating: Buy Maintain
14/02/2018 Broker: SunTrust Rating: Buy New Target: $10.0 Maintain
14/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Old Target: $24 Downgrade
12/02/2018 Broker: FBR Capital Rating: Buy New Target: $11.0 Initiate
12/02/2018 Broker: B. Riley & Co Rating: Buy New Target: $11 Initiates Coverage On

The stock decreased 1.86% or $0.06 during the last trading session, reaching $3.17. About 645,971 shares traded. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has declined 65.91% since April 23, 2017 and is downtrending. It has underperformed by 77.46% the S&P500.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $163.67 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.